Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crofelemer - Napo Pharmaceuticals

Next Previous
Drug Profile

Crofelemer - Napo Pharmaceuticals

Alternative Names: CRO-HIV; CRO-IBS; CRO-ID; CRO-PED; Fulyzaq; Mytesi; Provir; SP 303; TRN-002; Virend

Latest Information Update: 12 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shaman Pharmaceuticals
  • Developer Napo Pharmaceuticals; Puma Biotechnology; Salix Pharmaceuticals; Shaman Pharmaceuticals; University of California at San Francisco
  • Class Antidiarrhoeals; Biopolymers; Chromans; Flavonoids; Phytotherapies; Small molecules
  • Mechanism of Action Chloride channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Diarrhoea
  • Phase II Irritable bowel syndrome; Short bowel syndrome
  • Clinical Phase Unknown Inflammatory bowel diseases
  • Discontinued Herpes simplex virus infections; Influenza virus infections

Most Recent Events

  • 22 Oct 2019 Napo Pharmaceuticals initiates a phase IV trial for Diarrhoea (in patients with HIV infection) in USA (NCT04192487)
  • 10 Oct 2019 Crofelemer - Jaguar Health is available for licensing in China as of 10 Oct 2019. www.jaguarhealth.gcs-web.com
  • 10 Oct 2019 Clinical trials in Inflammatory bowel diseases in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top